With new promising results for its diabetes drug, is Sanofi a good investment right now?
News & Analysis: Sanofi
SNY earnings call for the period ending September 30, 2019.
It’s rejected a pair of drugs in the last six months.
Sanofi, Realty Income, and Dick's Sporting Goods might just serve up more refreshing returns than the beverage giant.
SNY earnings call for the period ending June 30, 2019.
SNY earnings call for the period ending March 31, 2019.
American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.
Novavax's experimental flu vaccine hits the mark in a highly anticipated midstage trial.
SNY earnings call for the period ending September 30, 2018.
This special kind of security is highly speculative and very rare.